Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project

FreeStyle Libre Continuous Glucose Monitoring

FreeStyle Libre Continuous Glucose Monitoring

Abbott® Freestyle Libre 2 Sensor - Continuous Glucose Monitoring Device (CGM) - Advanced Diabetes Supply®

Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases

Abbott's Freestyle Libre system becomes first CGM to be FDA cleared for use without fingersticks

Military Members, Families And Retirees Get Simplified Access To Abbott's Freestyle® Libre 2 System Through Tricare®

FreeStyle Libre 2 Continuous Glucose Monitor

FreeStyle Libre 3: World's Smallest Sensor

Healthy Living Now Providing the Abbott Freestyle Libre to Medicare Members — Healthy Living Medical Supply

FreeStyle Libre 2 System (CGM)

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

Freestyle Libre 2 - Continuous Glucose Monitoring System

What Is FreeStyle Libre 2? – The James Clinic Functional Doctor

Abbott FreeStyle Libre 2

FreeStyle Libre 2 Reader with Sensor Starter Kit for Continuous Glucose Monitoring

Freestyle Libre 2 Reader Kit

Better Living Now - Health Care Products, Programs and Services